Table 1. Prevalence of NAFLD among lean and non-obese subjects.
| StudyRef | Country | n | Mode of diagnosis | Prevalence | |
| Non-obese/Lean | Obese/Overweight | ||||
| Younossi et al.12 | United States | 11,613 | USG | 9.6% | 28.8% |
| Xu et al.16 | China | 6,905* | USG | 7.2% | Not studied |
| Das et al.3 | India | 1,911 | USG/CT** | 5.1% | 31.7% |
| Kwon et al.14 | Korea | 29,994 | USG | 12.6% | 50.1% |
| Bellentani et al.13 | Italy | 257 | USG | 16.4% | 75.8% |
| Sinn et al.15 | Korea | 5,878* | USG | 27% (non-obese) 16% (lean) |
Not studied |
| Wei et al.18 | Hong Kong | 911 | MRS | 19.3% | 60.5% |
*
Only non-obese population.
**
CT scan was used during second phase to confirm NAFLD.
Abbreviations: CT, computed tomography; MRS, magnetic resonance spectroscopy; USG, ultrasonography.